Detection of HIV-1 dual infections in highly exposed treated patients

Virol J. 2011 Aug 8:8:392. doi: 10.1186/1743-422X-8-392.

Abstract

Background: Genetic characterization of HIV-1 in Argentina has shown that BF recombinants predominate among heterosexuals and injecting drug users, while in men who have sex with men the most prevalent form is subtype B.

Objectives: The aim of this work was to investigate the presence of HIV dual infections in HIV-infected individuals with high probability of reinfection

Study design: Blood samples were collected from 23 HIV positive patients with the risk of reinfection from Buenos Aires. A fragment of the HIV gene pol was amplified and phylogenetic analyses were performed. Antiretroviral drug resistance patterns of all the sequences were analyzed.

Results: Five dual infections were detected with four patients coinfected with subtype B and BF recombinants and one patient was coinfected with two BF recombinants presenting different recombination patterns. Prolonged infection with a stable clinical condition was observed in the five individuals. Resistance mutation patterns were different between the predominant and the minority strains.

Conclusions: Our results show that HIV dual infection can occur with closely related subtypes, and even with different variants of the same recombinant form in certain populations. Clinical observations showed neither aggressive disease progression nor impact on the resistance patterns in the dually-infected patients.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / pharmacology
  • Argentina
  • Blood / virology
  • Cluster Analysis
  • Drug Resistance, Viral
  • HIV Infections / drug therapy*
  • HIV Infections / virology*
  • HIV-1 / classification*
  • HIV-1 / genetics
  • HIV-1 / isolation & purification*
  • Humans
  • Male
  • Mutation, Missense
  • Phylogeny
  • Polymerase Chain Reaction
  • Sequence Analysis, DNA
  • pol Gene Products, Human Immunodeficiency Virus / genetics

Substances

  • Anti-HIV Agents
  • pol Gene Products, Human Immunodeficiency Virus